Article, see p 2357 I t is now well established that observational studies seeking evidence that a risk factor causes a disease are susceptible to various biases. Among the most important are residual confounding, whereby unmeasured or imprecisely measured confounders prevent causal inferences being drawn from associations between any 2 parameters, and reverse causality. Although the former is typically acknowledged in reports of such studies, the latter concept appears to be less well understood and, therefore, is more often overlooked as a potential explanation for apparent, often unexpected, associations between risk factors and adverse outcomes.
were taking antihypertensive medications, allowing the researchers to argue that their findings demonstrate an innate (ie, nonpharmacological) accelerated terminal decline in SBP as individuals approach death, a pattern that would confound the relevant observational studies that have cast doubt on the safety and efficacy of BP lowering in the elderly. Consequently, the authors conclude that randomized evidence rather than observational data should inform clinical guidelines in this area. We strongly agree. That SBP declines more rapidly in those individuals closer to dying means this is a clear case where reverse causality in observational data (ie, a premorbid condition altering a risk factor, rather than the reverse) can prompt incorrect assumptions about the direction of causation.
Why BP falls to such an extent in those about to die requires further study but falling weight could certainly be a factor. In addition, as the authors point out, systemic inflammation (common in many chronic diseases, eg, heart failure, cancers, renal disease, autoimmune conditions) is often linked to deteriorating nutritional status (ie, lower caloric intake) toward the end of life and could directly or indirectly contribute to both weight loss and declines in BP.
Interestingly, the notion that poor health conditions leading to low BP could explain the J-shaped association of both SBP and diastolic BP levels with adverse outcomes was proposed more than a decade ago by Boutitie and colleagues. 4 Low levels of both SBP and diastolic BP were noted by these authors to be related to risk for cardiovascular and, informatively, also noncardiovascular outcomes in the control groups of BP trials; such associations could therefore not be attributed to antihypertensive treatment.
Taking a wider context, these new BP findings of reverse causality should serve as an alert to researchers seeking causal inferences from observational studies. Reverse causality is more often in play than one might imag- Recognition that glucose levels can decline with some chronic illnesses, eg, renal disease, and with unintentional weight loss Genetic epidemiology predicts higher cardiovascular disease and mortality risks with higher glucose 12 Vitamin D Low vitamin linked to adverse outcomes in many diseases 13 Ill people go outside less often so are less exposed to sunlight 13 Vitamin D is an acute phase reactant and declines with the inflammatory cytokine rise in acute and chronic diseases 13 No evidence from randomized trials that vitamin D supplementation lessens mortality risks in such conditions Alcohol intake Nondrinkers are at higher risks of cardiovascular disease than moderate drinkers
Genetically associated lower alcohol intake is associated with lower, not higher, cardiovascular disease, blood pressure, and weight 14 BMI indicates body mass index.
ine. Take, for example, the issue of sedentary activity or sitting time, an area given plentiful prominence in recent years as a cause of adverse cardiometabolic outcomes. 5 Illness will lead individuals to sit down more often (because of tiredness and fatigue) and watch more television than they would have when their health was better. This means that studies simply investigating the association between sedentary activity and adverse outcomes, but not excluding all those with known ill health at baseline, may substantially overestimate the importance of sedentary activity to adverse outcomes. This point was appreciated by Ekelund and colleagues 6 in their recent relevant meta-analysis that concluded that "high levels of moderate intensity physical activity (ie, about 60-75 minutes per day) seem to eliminate the increased risk of death associated with high sitting time." 6 In this meta-analysis, to lessen chances of reverse causality, the authors chose studies that either excluded individuals who had ill health from some (although not all) important causes at baseline or studies that excluded deaths occurring in the first 1 or 2 years of follow-up. Even with perfect cataloguing of risk factors and concomitant illnesses, however, the influence of reverse causality cannot be entirely removed, in part because of the presence of subclinical illness.
The issue of subclinical disease is relevant to many areas of epidemiological research including sedentary activity and other lifestyle behaviors, for example: adiposity (weight can fall or change its trajectory well before any clinical diagnosis of ill health and, in some cases, many years before death); intake of alcohol (a well-known phenomenon of sick quitters whereby ill health leads individuals to curtail or stop drinking alcohol); and physical activity levels per se (ill people have less energy to expend). Observational studies, however large, cannot offer definitive conclusions regarding cause and effect, particularly when issues of reverse causality can influence multiple key exposures, thereby potentially exaggerating the strengths of associations. Trials testing change in sedentary behavior are ongoing, albeit based on surrogate cardiovascular outcomes, and these should better inform relevant guidelines, although the general message to be more physically active is of course entirely justifiable based on other stronger data, including some trials.
There are many other pertinent examples where reverse causality can muddy findings in cardiovascular research (see Table for specific examples).
It is notable that the observational association of low cholesterol levels with higher cancer risk has been shown to not be causal in statin trials that show no increase in cancer rates. 9 Furthermore, by using serial trial data, we demonstrated that cholesterol levels decline more quickly in advance of incident cancers than participants who remained cancer free, 8 a finding in line with reverse causality and potentially attributable to systemic inflammation in cancers driving down circulating cholesterol levels.
These observations lead one to ask what statistical methods beyond serial tracking of data could help uncover reverse causality or else attenuate its influence in data analyses. There is no one definitive method. Rather, a series of approaches, all dependent on the availability of different types of data, is often needed. The recent Global BMI mortality collaboration provides a recent good example in the controversial adiposity area. 7 This latter study concluded that both overweight and obesity were associated with higher all-cause mortality. To limit reverse causality in this article, we (N.S. was coauthor) took several steps: (1) we examined the data only for never-smokers (given smoking lowers weight yet increases mortality), (2) we removed those with chronic diseases (as far as pragmatically possible), and (3) we excluded all deaths in the first 5 years of follow-up. In addition, we looked at the associations between BMI and mortality within differing age groups and were able to demonstrate a stronger association in younger age groups. This latter finding is important, because the youngest group is least likely to be afflicted by reverse causality and, thus, associations of adiposity with mortality in the younger groups provide more confidence in a stronger, likely causal, relationship.
Last, the emerging area of genetics could help further uncover reverse causality because any common polymorphisms that mark life-long differences in risk factors (without influencing other pathways) can be used as instruments of life-long exposure to such risk factors. Returning to the example of cholesterol and cancer-in the same report in which we showed that cholesterol levels fall before cancer diagnosis, we also demonstrated that those with genetically lower cholesterol levels did not have higher cancer outcomes, 8 replicating the robust results pooled from the statin trials. 9 Similarly, other genetic data support causal links between obesity and higher mortality, and between other commonly measured risk factors (lipids, glycemia) 12, 15 and cardiovascular events, as well. Genetic studies have also challenged the longassumed protective effect of alcohol on cardiovascular disease.
14 However, although such genetic studies can overcome many of the limitations inherent in observational studies that seek evidence of causal relationships between risk factor and disease, this type of work is itself not completely without potential bias and so should not be considered in isolation.
In summary, the study by Ravindrarajah and colleagues is a timely reminder that many potential biases including, but not limited to, reverse causality should be borne in mind in epidemiological analyses that seek to make causal inferences.
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